NCT00721422View on ClinicalTrials.gov

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

PHASE1TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Renal InsufficiencyPharmacokinetics

Interventions

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

DRUG

PD 0332334

50 mg (two 25 mg capsules), single, oral dose

Trial Locations (2)

33169

Pfizer Investigational Site, Miami

90630

Pfizer Investigational Site, Cypress

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY